AbbVie will pay $31.26 per share in cash for ImmunoGen, a 95% premium over the stock’s $16.06 close the day before. The price works out to $10.1 billion, and what AbbVie is buying is mostly one drug: Elahere, an antibody-drug conjugate (ADC) for ovarian cancer.
The boards of both companies have approved the deal. It is expected to close in the middle of 2024, subject to ImmunoGen shareholder approval, regulatory approvals and other customary conditions. AbbVie expects it to add to diluted earnings per share beginning in 2027.
The drug behind the price
Elahere is a first-in-class ADC approved for platinum-resistant ovarian cancer. It won accelerated approval from the FDA in November 2022, as the first targeted medicine to show a meaningful survival benefit in that setting. It targets folate receptor alpha with a maytansinoid payload called DM4, a potent tubulin inhibitor meant to kill the cells it reaches.
Sales have climbed. Elahere brought in $105.164 million in net product revenues in the third quarter, which gave ImmunoGen its first profitable quarter, with net income of $30.748 million. Over the first nine months of 2023 the drug took in $212.079 million, though the company still carried a net loss of $163.921 million for that period. In May, GlobalData projected peak annual sales of $615 million by 2029.
AbbVie sees a potential multi-billion-dollar treatment, with room to push into earlier lines of therapy and bigger segments of the ovarian cancer market. Positive Phase III results from the MIRASOL confirmatory trial are meant to support two filings: a Marketing Authorization Application in the European Union and a supplemental Biologic License Application to the FDA for full approval.
Pipeline and fit
AbbVie also inherits ImmunoGen’s follow-on candidates. IMGN-151 is a Phase I anti-FRα ADC for ovarian cancer that could extend to other solid tumors. Pivekimab sunirine, a Phase II anti-CD123 ADC, targets blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer, and holds the FDA’s breakthrough therapy designation for relapsed or refractory disease.
Oncology was AbbVie’s third largest source of product revenue in the third quarter, at $1.512 billion from Imbruvica, Venclexta and Epkinly. The company said its oncology pipeline includes more than 20 candidate drugs in more than 300 clinical trials, covering 31 development programs.
“The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy,” said Richard A. Gonzalez, AbbVie’s chairman and CEO. He added that the two companies “have the potential to transform the standard of care for people living with cancer.”
Mark Enyedy, ImmunoGen’s president and CEO, called the deal “the culmination of our 40-year commitment to develop and deliver the next-generation of ADCs.”
Analyst view
Andy T. Hsieh, a biotechnology analyst at William Blair, wrote that the deal “validates the clinical and commercial performance of Elahere” and that AbbVie “will likely be recognized as a formidable player in the ADC space.” His firm cut its rating on ImmunoGen to “Market Perform” because it does not expect a competing bid.
Israel Stern of GlobalData noted that platinum therapies have been the standard of care for epithelial ovarian, fallopian and primary peritoneal cancers. Patients who stop responding have received other cytotoxic agents, including liposomal doxorubicin, paclitaxel and topotecan. ImmunoGen believes Elahere will replace those as the standard.





